Prabhakar Baliga to Antilymphocyte Serum
This is a "connection" page, showing publications Prabhakar Baliga has written about Antilymphocyte Serum.
Connection Strength
1.253
-
Clinical and economic analysis of delayed administration of antithymocyte globulin for induction therapy in kidney transplantation. Prog Transplant. 2013 Mar; 23(1):33-8.
Score: 0.432
-
Comparison of efficacy of induction therapy in low immunologic risk African-American kidney transplant recipients. Transpl Int. 2010 May 01; 23(5):500-5.
Score: 0.344
-
Cytolytic Induction Therapy Improves Clinical Outcomes in African-American Kidney Transplant Recipients. Ann Surg. 2017 09; 266(3):450-456.
Score: 0.148
-
Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation. Ann Surg. 2014 May; 259(5):888-93.
Score: 0.117
-
Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantation. Clin Transplant. 2010 Jan-Feb; 24(1):40-7.
Score: 0.082
-
Long-term efficacy of induction therapy with anti-interleukin-2 receptor antibodies or thymoglobulin compared with no induction therapy in renal transplantation. Transplant Proc. 2008 Dec; 40(10):3401-7.
Score: 0.081
-
Transplanting Sensitized Kidney Transplant Patients With Equivalent Outcomes Utilizing Stringent HLA Crossmatching. Exp Clin Transplant. 2017 Feb; 15(1):47-55.
Score: 0.034
-
Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis. 2004 Sep; 6(3):101-9.
Score: 0.015